Microsoft is working to resolve a known issue that causes its Defender for Endpoint enterprise endpoint security platform to ...

Microsoft confirms a Defender for Endpoint bug mislabels SQL Server 2017 and 2019 as end-of-life. A fix is now rolling out.

Microsoft Defender incorrectly reports SQL Server 2017 and 2019 as end-of-life - but don't worry, it's an error.

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...

Background Traditional estimates of SCD incidence in US high school athletes 1 athlete death per 200 000–400 000 athlete-years. Objective To investigate the rate of SCA/SCD in high school athletes ...

1 Departments of Family Medicine and Orthopaedics and Sports Medicine, University of Washington, Seattle, Washington, USA 2 Department of Family Medicine, University of Washington, Seattle, Washington ...

Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of participants with severe sickle cell disease. The therapy led to substantial ...

A Virginia man used both his bad and good luck for the day by crashing near a cardiologist’s office after having a heart attack. The Virginia Beach local has been given a second chance at life thanks ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.